Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
NYSE:BIO
Bio-Rad Laboratories (BIO) Stock Price & Analysis
798 Followers
BIO Stock Chart & Stats
Day’s Range$268.33 - $279.7
52-Week Range― - ―
Previous Close$269.75
Volume383.48K
Average Volume (3M)N/A
Market Cap
$7.71B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 07, 2024EPS Estimate
$2.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$411.25Price Target Upside50.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bio-Rad Laboratories News
PremiumMarket News
SPY ETF Update, 4/29/2024 
PremiumMarket News
SPY ETF Update, 4/25/2024 
PremiumCompany Announcements
Bio-Rad Laboratories: Executive Transition and Shareholder Decisions
PremiumCompany Announcements
Bio-Rad Exec VP Andrew Last Announces Retirement Plans
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe company is launching the QX Continuum this year, which will expand its focus and continues to focus on assay expansion, with more launches coming.
Operational EfficiencyManagement expects Life Sciences to recover, with a focus on increasing volumes and maintaining cost-controls.
Stock PotentialAnalyst predicts a potential share price return of 22.7%, suggesting an overall positive outlook for the investment.
Bears Say
Financial OutlookVisibility for process chromatography sales is lower than usual, indicating uncertainty in the near-term revenue projections.
Profit MarginsThe margin guide was underwhelming with adjusted operating profit margin down due to wage inflation and other expenses.
Sales PerformanceLife Sciences segment faces challenges due to weaker demand and headwinds from China, impacting ddPCR and process chromatography sales.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BIO FAQ
What was Bio-Rad Laboratories’s price range in the past 12 months?
Currently, no data Available
What is Bio-Rad Laboratories’s market cap?
Currently, no data Available
When is Bio-Rad Laboratories’s upcoming earnings report date?
Bio-Rad Laboratories’s upcoming earnings report date is May 07, 2024 which is in 5 days.
How were Bio-Rad Laboratories’s earnings last quarter?
Bio-Rad Laboratories released its earnings results on Feb 15, 2024. The company reported $3.1 earnings per share for the quarter, beating the consensus estimate of $2.818 by $0.282.
Is Bio-Rad Laboratories overvalued?
According to Wall Street analysts Bio-Rad Laboratories’s price is currently Undervalued.
Does Bio-Rad Laboratories pay dividends?
Bio-Rad Laboratories does not currently pay dividends.
What is Bio-Rad Laboratories’s EPS estimate?
Bio-Rad Laboratories’s EPS estimate is $2.15.
How many shares outstanding does Bio-Rad Laboratories have?
Currently, no data Available
What happened to Bio-Rad Laboratories’s price movement after its last earnings report?
Bio-Rad Laboratories reported an EPS of $3.1 in its last earnings report, beating expectations of $2.818. Following the earnings report the stock price went up 3.587%.
Which hedge fund is a major shareholder of Bio-Rad Laboratories?
Among the largest hedge funds holding Bio-Rad Laboratories’s share is Southeastern Asset Management Inc. It holds Bio-Rad Laboratories’s shares valued at 118M.
---
Bio-Rad Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$411.25 (50.06% Upside)
$411.25 (50.06% Upside)
Blogger Sentiment
Bullish
BIO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 127.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.16%
12-Months-Change
Fundamentals
Return on Equity
-6.94%
Trailing 12-Months
Asset Growth
-8.91%
Trailing 12-Months
Company Description
Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the following segments: Life Sciences and Clinical Diagnostics. The Life Science segment develops, manufactures and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialize in quality controls that serve clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
---
BIO Earnings Call
Q4 2024
0:00 / 0:00
---
BIO Net sales Breakdown
55.75% Clinical Diagnostics
44.11% Life Science
0.13% Other
---
BIO Stock 12 Months Forecast
Average Price Target
$411.25
▲(50.06% Upside)
Technical Analysis
Best Analysts Covering BIO
1 Year
1 Year Success Rate
23/33 ratings generated profit
1 Year Average Return
+19.28%
reiterated a buy rating 3 months ago
Copying Brandon Couillard's trades and holding each position for 1 Year would result in 69.70% of your transactions generating a profit, with an average return of +19.28% per trade.
---